Zariana Nikolova

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>

Charles D. Blanke, George D. Demetri, Margaret von Mehren et al. · Journal of Clinical Oncology · 2008 · 1K citations · Full text

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

Jane F. Apperley, Martine Gardembas, Junia V. Melo et al. · New England Journal of Medicine · 2002 · 630 citations · Full text

Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225

Grant A. McArthur, George D. Demetri, A. van Oosterom et al. · Journal of Clinical Oncology · 2005 · 477 citations

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

George D. Demetri, Yanfeng Wang, Elisabeth Wehrle et al. · Journal of Clinical Oncology · 2009 · 396 citations · Full text

Surgical Oncology, Pathology, Pharmacotherapy +16

Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)

Michael C. Heinrich, Grant A. McArthur, George D. Demetri et al. · Journal of Clinical Oncology · 2006 · 315 citations